Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

The success rate of salvage radiation after prostatectomy differs by patients’ PSA. Only a subset of patients with biochemically recurrent prostate cancer after radical prostatectomy (RP) will develop ...

Alpha Tau Medical Ltd ($DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

Hypofractionation of radiation therapy in men with high-risk prostate cancer is not associated with worse overall survival or prostate cancer mortality. Survival outcomes are comparable after ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...